| ID | 1197 |
| Name of the vaccine | GVXN SD133 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Bioconjugate |
| Nucleic acid content | DNA |
| Age | 18 to 50 years |
| Description of the vaccine | Shigella dysenteriae vaccine. |
| Name of the manufacturer | GlycoVaxyn AG |
| Name of the manufacturing country | Switzerland |
| Year of manufacture | 2010 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Two doses, gap of 8 weeks. |
| Mechanism of action | O1 specific humoral response. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without Aluminium hydroxide |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 26162850 |
| Clinical trial number | NCT01069471 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|